Allen J

Massachusetts General Hospital

1
Publications in this database

PubMed name variants: Allen J. Uses the same surname-and-first-initial grouping as the researcher table; matches are not verified identities.

1
Career-wide h-index · OpenAlex
(5 citations, 2 total works)

Career-wide Research Topics · OpenAlex

Topic counts cover the OpenAlex author’s full publication record, across all conditions.

Multiple Sclerosis Research Studies (1)Blood transfusion and management (1)Cardiac and Coronary Surgery Techniques (1)Transplantation: Methods and Outcomes (1)Autoimmune Neurological Disorders and Treatments (1)

Erythromelalgia Publications

Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy: Longitudinal Tracking Through 10 Years Including Pregnancies.

Oaklander AL, Allen J, Dietliker N, Wilder-Smith EP
Neurology(R) neuroimmunology & neuroinflammation •

To expand understanding of the pathogenesis, presentations, and treatment of initially idiopathic small fiber polyneuropathy (SFN). We longitudinally readministered validated metrics to track disease course and treatment responses in a previously healthy woman with acute, postinfectious, skin biopsy-confirmed, idiopathic SFN. During 5 years, viral respiratory infections triggered 3 separated episodes of acute, disabling burning hand, foot, and face pain (erythromelalgia). The initial 2 resolved with high-dose prednisone, and the third responded to repeated immunoglobulin treatments. Pregnancy with miscarriage triggered a fourth exacerbation refractory to corticosteroids and cyclosporin. Immunoglobulins restored total remission for 2 months; then, 2 rituximab doses slightly improved later flaring. Subsequently, daratumumab initiated 100-day remission later maintained by belimumab, initiated to permit another pregnancy. Remission continued after gestational week 13 all-treatment withdrawal. A week 30 fifth flare responded to plasmapheresis, with healthy birth at week 40. At 11-week postpartum, as symptoms returned, restarting belimumab restored remission maintained during ≥19 months of breastfeeding. This decade of tracking characterizes a relapsing-remitting course of SFN with initially separated monophasic episodes becoming more confluent, as with multiple sclerosis. This tempo and responsiveness to 5 immunotherapies suggest dysimmune causality. Validated metrics helped define the course and track treatment efficacy, particularly during pregnancy and breastfeeding. This is a single observational study without controls. This provides Class IV evidence.